Form 4 Filing for Ascendis Pharma A/S

Jean Jacques Bienaime, a director at Ascendis Pharma A/S, reported a disposition of 9160 warrants on April 14, 2026. These warrants, with an exercise price of 172.35, were set to vest starting June 10, 2026, with 25% vesting on that date and the remainder in 36 equal monthly installments. The disposition resulted in 0 post-transaction shares. Concurrently, Bienaime was awarded a new set of 9160 warrants as part of his appointment to the board. These new warrants have an exercise price of 249.84 and vest starting April 14, 2027, with 25% vesting on that date and the remainder in 36 equal monthly installments. The disposition and acquisition are linked to the cancellation of a previously granted warrant and the issuance of a new one. The reporting owner holds these securities directly.